EUVIMEDEUVIMED entdecken
Open Access

CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice

Ralf S Schmid, Xuefeng Deng, Priyalakshmi Panikker, Msema Msackyi, Camilo Breton, James M Wilson

Journal of Clinical Investigation · 01.03.2021 · 131 (5)

DOI: 10.1172/jci142574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.03.2021. Verfasst von Ralf S Schmid und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene editing holds the potential to correct mutations and cure devastating genetic disorders. The technology has not yet proven efficacious for therapeutic use in CNS diseases with ubiquitous neuronal defects. Angelman syndrome (AS), a severe neurodevelopmental disorder, is caused by a lack of maternal expression of the UBE3A gene. Because of genomic imprinting, only neurons are affected. One therapeutic approach focuses on the intact paternal UBE3A copy in patients with AS that is silenced by an antisense transcript (UBE3A-ATS). We show here that gene editing of Ube3a-ATS in the mouse brain resulted in the formation of base pair insertions/deletions (indels) in neurons and the subsequent unsilencing of the paternal Ube3a allele in neurons, which partially corrected the behavioral phenotype of a murine AS model. This study provides compelling evidence to further investigate editing of the homologous region of the human UBE3A-ATS because this may provide a lasting therapeutic effect for patients with AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGene EditingAngelman SyndromeAnimalsBrainHumansMiceRNA, AntisenseUbiquitin-Protein Ligases

Stichwörter der Autor:innen

Gene therapyGenetic diseasesGeneticsMouse modelsNeuroscience

Substanzen

RNA, AntisenseUbe3a protein, mouseUbiquitin-Protein Ligases

Förderung

  • University of Pennsylvania

Zitieren

APA

Schmid, R. S., Deng, X., Panikker, P., Msackyi, M., Breton, C., & Wilson, J. M. (2021). CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. Journal of Clinical Investigation, 131(5). https://doi.org/10.1172/jci142574

Vancouver

Schmid RS, Deng X, Panikker P, Msackyi M, Breton C, Wilson JM. CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. Journal of Clinical Investigation. 2021;131(5). doi:10.1172/jci142574

BibTeX
@article{Schmid2021,
  author = {Schmid, Ralf S and Deng, Xuefeng and Panikker, Priyalakshmi and Msackyi, Msema and Breton, Camilo and Wilson, James M},
  title = {CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice},
  journal = {Journal of Clinical Investigation},
  year = {2021},
  volume = {131},
  number = {5},
  doi = {10.1172/jci142574}
}
Kostenlos starten →